Collegium Pharmaceutical, Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Collegium Pharmaceutical, Inc. (COLL) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $10.79 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-03-07
- Collegium Pharmaceutical, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $10.79M, a 728.40% increase year-over-year.
- Collegium Pharmaceutical, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $11.95M, a 2828.92% increase year-over-year.
- Collegium Pharmaceutical, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $3.56M.
- Collegium Pharmaceutical, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $2.17M.
- Collegium Pharmaceutical, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $28.48M, a 1564.29% increase from fiscal 2016.
- Collegium Pharmaceutical, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $1.71M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $10.79M 10-K · filed 2018-03-07 | $22.74M derived: sum of 2 quarters · filed 2018-03-07 | $26.30M derived: sum of 3 quarters · filed 2018-03-07 | $28.48M 10-K · filed 2018-03-07 |
| 2017-09-30 | $11.95M 10-K · filed 2018-03-07 | $15.51M derived: sum of 2 quarters · filed 2018-03-07 | $17.68M 10-Q · filed 2017-11-08 | $18.98M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $3.56M 10-K · filed 2018-03-07 | $5.73M 10-Q · filed 2017-08-09 | $7.04M derived: sum of 3 quarters · filed 2018-03-07 | $7.44M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $2.17M 10-K · filed 2018-03-07 | $3.48M derived: sum of 2 quarters · filed 2018-03-07 | $3.88M derived: sum of 3 quarters · filed 2018-03-07 | |
| 2016-12-31 | $1.30M 10-K · filed 2018-03-07 | $1.71M derived: sum of 2 quarters · filed 2018-03-07 | $1.71M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $408.00K 10-K · filed 2018-03-07 | $408.00K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |